At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Pierre Gholam, MD
Advertisement
Articles by Pierre Gholam, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
4
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
5